Catalogue Search | MBRL
Are you sure you want to remove the book from the shelf?
{{itemTitle}}
11
result(s) for
"Rake, Matthew"
Sort by:
Creepy, crawly creatures
\"Look closely at the ten most amazing insects and spiders that buzz, dart, and hang out all over the world. Beware those bites and stings as you encounter a hornet that will chase humans, a louse that lives on a fish's tongue, a centipede that will fight snakes, and more\"--Amazon.com.
Book
The resurrection
Rake reviews Ships of Mercy: The Remarkable Fleet Bringing Hope to the World's Forgotten Poor by Don Stephens with Lynda Rutledge Stephenson.
Book Review
Creatures of the rain forest
\"Track down the ten most awe-inspiring animals in the rain forests of the world. Step away from those jaws, claws, and muscles, because here you'll find: the largest snake in the world, blood-sucking vampires, an eel that kills its prey with electric shocks... Come face to face with these extreme animals and learn their secrets!\"--Publisher's website.
Book
Scaly, slippery creatures
\"Can you name the most poisonous snake on Earth? Can you tell the difference between a Komodo dragon and a crocodile? Meet some of the world's creepiest critters in this photo-packed book of reptilian monsters\"-- Provided by publisher.
Book
Will this be Africa's World Cup
Nigeria, South Africa, Cameroon, Tunisia and Morocco will be playing in the 1998 World Cup finals in France. A look at Zaire's performance in 1974, Tunisia's performance in 1978, Morocco's performance in 1986, and Cameroon's performance in 1994 is offered. Several other World Cup playoffs by African nations are noted.
Magazine Article
Review: 2006: The Readers' View: ART
Everybody has been raving about Velasquez at the National Gallery but did anyone notice the video installation by [EVE SUSSMAN] & the Rufus Corporation, inspired by Velasquez's masterpiece Las Meninas ? This jewel of a film captures a few moments in the artist's salon, when courtiers, maids and a jester fuss around the Infanta as she is prepared for her portrait. Pure inspiration and a new insight into the approach of the old master.
Newspaper Article
Integrating 4 methods to evaluate physical function in patients with cancer (In4M): protocol for a prospective cohort study
IntroductionAccurate, patient-centred evaluation of physical function in patients with cancer can provide important information on the functional impacts experienced by patients both from the disease and its treatment. Increasingly, digital health technology is facilitating and providing new ways to measure symptoms and function. There is a need to characterise the longitudinal measurement characteristics of physical function assessments, including clinician-reported outcome, patient-reported ported outcome (PRO), performance outcome tests and wearable data, to inform regulatory and clinical decision-making in cancer clinical trials and oncology practice.Methods and analysisIn this prospective study, we are enrolling 200 English-speaking and/or Spanish-speaking patients with breast cancer or lymphoma seen at Mayo Clinic or Yale University who will receive intravenous cytotoxic chemotherapy. Physical function assessments will be obtained longitudinally using multiple assessment modalities. Participants will be followed for 9 months using a patient-centred health data aggregating platform that consolidates study questionnaires, electronic health record data, and activity and sleep data from a wearable sensor. Data analysis will focus on understanding variability, sensitivity and meaningful changes across the included physical function assessments and evaluating their relationship to key clinical outcomes. Additionally, the feasibility of multimodal physical function data collection in real-world patients with breast cancer or lymphoma will be assessed, as will patient impressions of the usability and acceptability of the wearable sensor, data aggregation platform and PROs.Ethics and disseminationThis study has received approval from IRBs at Mayo Clinic, Yale University and the US Food and Drug Administration. Results will be made available to participants, funders, the research community and the public.Trial registration numberNCT05214144; Pre-results.
Journal Article
Common Variants at 10 Genomic Loci Influence Hemoglobin A1C Levels via Glycemic and Nonglycemic Pathways
OBJECTIVE: Glycated hemoglobin (HbA1c), used to monitor and diagnose diabetes, is influenced by average glycemia over a 2- to 3-month period. Genetic factors affecting expression, turnover, and abnormal glycation of hemoglobin could also be associated with increased levels of HbA1c. We aimed to identify such genetic factors and investigate the extent to which they influence diabetes classification based on HbA1c levels. RESEARCH DESIGN AND METHODS: We studied associations with HbA1c in up to 46,368 nondiabetic adults of European descent from 23 genome-wide association studies (GWAS) and 8 cohorts with de novo genotyped single nucleotide polymorphisms (SNPs). We combined studies using inverse-variance meta-analysis and tested mediation by glycemia using conditional analyses. We estimated the global effect of HbA1c loci using a multilocus risk score, and used net reclassification to estimate genetic effects on diabetes screening. RESULTS: Ten loci reached genome-wide significant association with HbA1c, including six new loci near FN3K (lead SNP/P value, rs1046896/P = 1.6 x 10-26), HFE (rs1800562/P = 2.6 x 10-20), TMPRSS6 (rs855791/P = 2.7 x 10-14), ANK1 (rs4737009/P = 6.1 x 10-12), SPTA1 (rs2779116/P = 2.8 x 10-9) and ATP11A/TUBGCP3 (rs7998202/P = 5.2 x 10-9), and four known HbA1c loci: HK1 (rs16926246/P = 3.1 x 10-54), MTNR1B (rs1387153/P = 4.0 x 10-11), GCK (rs1799884/P = 1.5 x 10-20) and G6PC2/ABCB11 (rs552976/P = 8.2 x 10-18). We show that associations with HbA1c are partly a function of hyperglycemia associated with 3 of the 10 loci (GCK, G6PC2 and MTNR1B). The seven nonglycemic loci accounted for a 0.19 (% HbA1c) difference between the extreme 10% tails of the risk score, and would reclassify similar to 2% of a general white population screened for diabetes with HbA1c. CONCLUSIONS: GWAS identified 10 genetic loci reproducibly associated with HbA1c. Six are novel and seven map to loci where rarer variants cause hereditary anemias and iron storage disorders. Common variants at these loci likely influence HbA1c levels via erythrocyte biology, and confer a small but detectable reclassification of diabetes diagnosis by HbA1c.
Journal Article
Preclinical efficacy of thioxanthone SR271425 against transplanted solid tumors of mouse and human origin
A highly active and broadly active thioxanthone has been identified: N-[[1-[[2-(Diethylamino)ethyl]amino]-7-methoxy-9-oxo-9H-thioxanthen++ +-4-yl] methylformamide (SR271425, BCN326862, WIN71425). In preclinical testing against a variety of subcutaneously growing solid tumors, the following %T/C and Log10 tumor cell kill (LK) values were obtained: Panc-03 T/C = 0, 5/5 cures; Colon-38 (adv. stage) T/C = 0, 3/5 cures, 4.9 LK; Mam-16/C T/C = 0, 3.5 LK; Mam-17/0 T/C = 0, 2.8 LK; Colon-26 T/C = 0, 1/5 cures, 3.2 LK; Colon-51 T/C = 0, 2.7 LK; Panc-02 T/C = 0, 3.1 LK; B16 Melanoma T/C = 13%, 4.0 LK; Squamous Lung-LC12 (adv. stage) T/C = 14%, 4.9 LK; BG-1 human ovarian T/C = 16%, 1.3 LK; WSU-Brl human breast T/C = 25%, 0.8 LK. The agent was modestly active against doxorubicin (Adr)-resistant solid tumors: Mam-17/AdrT/C =23%, 0.8 LK; and Mam-16/C/Adr T/C = 25%, 1.0 LK, but retained substantial activity against a taxol-resistant tumor: Mam-16/C/taxol T/C = 3%, 2.4 LK. SR271425 was highly active against IV implanted leukemias, L1210 6.3 LK and AML1498 5.3 LK. The agent was equally active both by the IV and oral routes of administration, although requiring approximately 30% higher dose by the oral route. Based on its preclinical antitumor profile, it may be appropriate to evaluate SR271425 in clinical trials.
Journal Article